Cargando…
Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900236/ https://www.ncbi.nlm.nih.gov/pubmed/30609008 http://dx.doi.org/10.1111/bjd.17604 |
| _version_ | 1783477311061884928 |
|---|---|
| author | Romiti, R. Valenzuela, F. Chouela, E.N. Xu, W. Pangallo, B. Moriarty, S.R. Gürbüz, S. Riedl, E. |
| author_facet | Romiti, R. Valenzuela, F. Chouela, E.N. Xu, W. Pangallo, B. Moriarty, S.R. Gürbüz, S. Riedl, E. |
| author_sort | Romiti, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6900236 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69002362019-12-20 Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis Romiti, R. Valenzuela, F. Chouela, E.N. Xu, W. Pangallo, B. Moriarty, S.R. Gürbüz, S. Riedl, E. Br J Dermatol Correspondence John Wiley and Sons Inc. 2019-03-11 2019-07 /pmc/articles/PMC6900236/ /pubmed/30609008 http://dx.doi.org/10.1111/bjd.17604 Text en © 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Correspondence Romiti, R. Valenzuela, F. Chouela, E.N. Xu, W. Pangallo, B. Moriarty, S.R. Gürbüz, S. Riedl, E. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| title | Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| title_full | Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| title_fullStr | Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| title_full_unstemmed | Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| title_short | Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| title_sort | prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900236/ https://www.ncbi.nlm.nih.gov/pubmed/30609008 http://dx.doi.org/10.1111/bjd.17604 |
| work_keys_str_mv | AT romitir prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT valenzuelaf prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT chouelaen prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT xuw prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT pangallob prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT moriartysr prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT gurbuzs prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis AT riedle prevalenceandoutcomeoflatenttuberculosisinpatientsreceivingixekizumabintegratedsafetyanalysisfrom11clinicaltrialsofpatientswithplaquepsoriasis |